


What is claimed is:

1. A compound represented by Formula (I):



wherein:

5 R^1 is selected from the group consisting of hydrogen, halo, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C1-C6) haloalkyl, hydroxy, (C1-C6) alkoxy, amino, (C1-C6) alkylamino, amide, sulfonamide, cyano, substituted or unsubstituted (C6-C10) aryl;

10 R^2 is selected from the group consisting of hydrogen, halo, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C1-C6) haloalkyl, hydroxy, (C1-C6) alkoxy, (C2-C8) alkoxyalkyl, amino, (C1-C6) alkylamino, (C6-C10) arylamino;

R^3 is selected from the group consisting of hydrogen, (C1-C6) alkyl, (C6-C10) aryl, (C5-C10) heteroaryl, and amide;

15 R^4 , R^5 and R^6 are independently selected from the group consisting of hydrogen and (C1-C6) alkyl; each R^7 is independently selected from the group consisting of hydrogen, (C1-C6) alkyl and hydroxyl;


20 R^8 is selected from the group consisting of hydroxy, (C1-C6) O-alkyl, (C3-C8) O-cycloalkyl, and NR^9R^{10} ; where R^9 and R^{10} are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C1-C6) hydroalkyl, (C1-C6) dihydroxyalkyl, (C1-C6) alkoxy, (C1-C6) alkyl carboxylic acid, (C1-C6) alkyl phosphoric acid, (C1-C6) alkyl sulfuric acid, (C1-C6) hydroxyalkyl carboxylic acid, (C1-C6) alkyl amide, (C3-C8) cycloalkyl, (C5-C8) heterocycloalkyl, (C6-C8) aryl, (C5-C8) heteroaryl, (C3-C8) cycloalkyl carboxylic acid, or R^9 and R^{10} together with

25 N forms a (C5-C8) heterocyclic ring either unsubstituted or substituted with one or more hydroxyls, ketones, ethers, and carboxylic acids; and

n and m are independently 0, 1, 2, or 3; p is 1, 2, or 3;


or, a pharmaceutically acceptable salt, its tautomer, a pharmaceutically acceptable salt of its tautomer, or a prodrug thereof.

2. The compound, salt, tautomer, or prodrug according to claim 1 selected from the group represented by the following structures:




5 wherein R² is selected from the group consisting of hydrogen and fluoro.

3. The compound, salt, tautomer, or prodrug according to claim 1 represented by the following structure:



4. The compound, salt, tautomer, or prodrug according to claim 1 represented by
10 Formula (II):



15 wherein R^{8a} is selected from the group consisting of hydrogen, (C1-C6) alkyl, and (C3-C8) cycloalkyl.

5. The compound, salt, tautomer, or prodrug according to claim 4, wherein:


R¹ and R² are independently selected from the group consisting of hydrogen and fluoro;

20 R³ and R⁴ are methyl;


R⁵, R⁶, R⁷ and R^{8a} are hydrogen; and

n and m are independently 0, 1, or 2.


6. The compound, salt, tautomer, or prodrug according to claim 5 selected from the group consisting of:



5 7. The compound, salt, tautomer, or prodrug according to claim 5 represented by the following structure:




8. The compound, salt, tautomer, or prodrug according to claim 5 represented by the following structure:



10

9. A compound, salt, tautomer, or prodrug according to claim 1 represented by Formula (III):



15 wherein R^{8a} is selected from the group consisting of hydrogen, (C1-C6) alkyl, and (C3-C8) cycloalkyl.

10. The compound, salt, tautomer, or prodrug according to claim 9, wherein:


R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro;

R^3 and R^4 are methyl;


5 R^5 , R^6 , and R^{8a} are hydrogen; and

n and p are independently 1, or 2.


11. The compound, salt, tautomer, or prodrug according to claim 10 selected from the group consisting of:



12. The compound, salt, tautomer, or prodrug according to claim 10 represented by the following structure:




15 13. The compound, salt, tautomer, or prodrug according to claim 10 represented by the following structure:




- 43 -

14. The compound, salt, tautomer, or prodrug according to claim 10 represented by the following structure:



15. A compound, salt, tautomer, or prodrug according to claim 9 represented by
5 Formula (IIIa):




wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro;

10 R^3 and R^4 are methyl;
 R^5 , R^6 , and R^{8a} are hydrogen; and
 n and p are 2.

16. A compound, salt, tautomer, or prodrug according to claim 15 represented by
15 Formula (IIIb):




wherein:

R^1 and R^2 are independently selected from the group consisting of hydrogen and fluoro; and

R^3 and R^4 are methyl.

17. A compound, salt, tautomer, or prodrug according to claim 1 represented by Formula (IV):



5

wherein R^8 is NR^9R^{10} .

18. The compound, salt, tautomer, or prodrug of claim 17, wherein:

10 R^1 and R^2 are independently selected from the group consisting of hydrogen, halo, cyano;

R^3 , R^4 , R^5 and R^6 are independently hydrogen or (C1-C6) alkyl;

R^7 is hydrogen, or hydroxyl;


15 n , and p are independently 1, or 2;

m is 0 or 1; and


R^9 and R^{10} are selected from the group consisting of hydrogen, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) dihydroxyalkyl, (C1-C6) alkoxy, (C1-C6) alkyl carboxylic acid, (C1-C6) alkyl phosphoric acid, (C1-C6) alkyl sulfuric acid, (C1-C6) hydroxyalkyl carboxylic acid, (C1-C6) alkyl amide, (C3-C8) cycloalkyl, (C5-C8) heterocycloalkyl, (C6-C8) aryl, (C5-C8) heteroaryl, (C3-C8) cycloalkyl carboxylic acid, or R^9 and R^{10} together with N forms a (C5-C8) heterocyclic ring either unsubstituted or substituted with one or more hydroxyls, ketones, ethers, and carboxylic acids.

25

19. The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:




20. The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:




5


21. The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




22. The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:



23. The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




24. The compound, salt, tautomer, or prodrug according to claim 18 represented by the following structure:




5 wherein n is 0, 1, or 2.

25. The compound, salt, tautomer, or prodrug according to claim 24 selected from the group represented by the following structures:




- 48 -


26. The compound, salt, tautomer, or prodrug according to claim 24 selected from the group represented by the following structures:



5 27. The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:




28. The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:



5

29. The compound, salt, tautomer, or prodrug according to claim 18 selected from the group represented by the following structures:




wherein:

R^2 is selected from the group consisting of hydrogen and fluoro; and

R^8 is selected from the group consisting of radicals represented by the

15 following structures:



30. The compound, salt, tautomer, or prodrug according to any of claims 1-29 with the following provisos:

- 5 the compound, salt, tautomer, or prodrug of claim 2 is excluded or
the compound, salt, tautomer, or prodrug of claim 3 is excluded or
the compound, salt, tautomer, or prodrug of claim 4 is excluded or
the compound, salt, tautomer, or prodrug of claim 5 is excluded or
the compound, salt, tautomer, or prodrug of claim 6 is excluded or
the compound, salt, tautomer, or prodrug of claim 7 is excluded or
the compound, salt, tautomer, or prodrug of claim 8 is excluded or
10 the compound, salt, tautomer, or prodrug of claim 9 is excluded or
the compound, salt, tautomer, or prodrug of claim 10 is excluded or
the compound, salt, tautomer, or prodrug of claim 11 is excluded or
the compound, salt, tautomer, or prodrug of claim 12 is excluded or
the compound, salt, tautomer, or prodrug of claim 13 is excluded or
15 the compound, salt, tautomer, or prodrug of claim 14 is excluded or
the compound, salt, tautomer, or prodrug of claim 15 is excluded or
the compound, salt, tautomer, or prodrug of claim 16 is excluded or
the compound, salt, tautomer, or prodrug of claim 17 is excluded or
the compound, salt, tautomer, or prodrug of claim 18 is excluded or
20 the compound, salt, tautomer, or prodrug of claim 19 is excluded or
the compound, salt, tautomer, or prodrug of claim 20 is excluded or
the compound, salt, tautomer, or prodrug of claim 21 is excluded or
the compound, salt, tautomer, or prodrug of claim 22 is excluded or
the compound, salt, tautomer, or prodrug of claim 23 is excluded or
25 the compound, salt, tautomer, or prodrug of claim 24 is excluded or
the compound, salt, tautomer, or prodrug of claim 25 is excluded or
the compound, salt, tautomer, or prodrug of claim 26 is excluded or
the compound, salt, tautomer, or prodrug of claim 27 is excluded or
the compound, salt, tautomer, or prodrug of claim 28 is excluded or
30 the compound, salt, tautomer, or prodrug of claim 29 is excluded or
the compound, salt, tautomer, or prodrug of claim 30 is excluded.

31. A method for the modulation of the catalytic activity of a protein kinase with a compound or salt of any one of claims 1-30.

32. The method of claim 31, wherein said protein kinase is selected from the
5 group consisting of VEGF receptors and PDGF receptors.